BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 20, 2005
View Archived Issues
Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin
A missed primary endpoint in a pivotal study of its lung cancer brain metastases drug, Xcytrin, sent Pharmacyclics Inc.'s stock plunging more than 64 percent Monday. (BioWorld Today)
Read More
Palatin Stops NeutroSpec Sales To Investigate Reported Deaths
Read More
Hypnion Extending Series B: $20M More For Phase II Bid
Read More
FDA Now Has sBLA For Avastin In Relapsed Colorectal Cancer
Read More
Other News To Note
Read More
ICAAC Roundup
Read More